Tag: Free radical scavenger

  • Edaravone

    Free radical scavenger

    A pyrazolone free radical scavenger; approved in Japan and the US for amyotrophic lateral sclerosis (ALS) and acute ischemic stroke.

    Abstract

    Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one; CAS 89-25-8; molecular formula C10H10N2O; molecular weight 174.20) is a pyrazolone free radical scavenger developed at Mitsubishi-Tokyo Pharmaceuticals. Originally approved in Japan in 2001 for acute ischemic stroke (Radicut), and in 2017 approved by the FDA for amyotrophic lateral sclerosis (Radicava). Mechanism: edaravone scavenges peroxyl, hydroxyl, and other reactive oxygen species, reducing oxidative damage to neurons and the surrounding glia in the affected region. The ALS approval was supported by a Japanese phase 3 trial (MCI186-19) demonstrating slowed functional decline (ALSFRS-R score) in a subset of patients with early disease and preserved respiratory function. Initially IV-only; an oral formulation (Radicava ORS) was approved in 2022. Plasma half-life is approximately 4.5 hours. Used as the canonical free radical scavenger in neurology research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.